[Use of levosimendan in cardiosurgical patients with chronic heart insufficiency]

Area of Science:

• Cardiology
• Pharmacology
• Critical Care Medicine

Background:

• Patients undergoing cardiosurgery with severe heart conditions like dilated cardiomyopathy or NYHA Class IV circulatory insufficiency face high risks.
• Optimizing hemodynamic stability and reducing postoperative complications are critical for improving outcomes in these vulnerable patients.

Purpose of the Study:

• To evaluate the impact of preoperative levosimendan on hemodynamic parameters, cardiotonic support, ICU stay, and mortality in high-risk cardiosurgical patients.
• To assess the efficacy of levosimendan as a pre-treatment strategy for improving surgical outcomes.

Main Methods:

• A prospective study involving 25 cardiosurgical patients with severe heart conditions who received levosimendan preoperatively (3-5 days before surgery).
• A control group of 22 similar patients who did not receive levosimendan was used for comparison.
• Hemodynamic parameters, cardiotonic drug requirements, ICU length of stay, and hospital mortality were monitored and compared between groups.

Main Results:

• Levosimendan administration resulted in statistically significant reductions in pulmonary artery pressure and pulmonary wedge pressure.
• The treatment group showed significant increases in cardiac index and left ventricular ejection fraction.
• Patients treated with levosimendan required lower doses of sympathomimetics, had shorter ICU stays, and exhibited lower mortality rates (p < 0.05).

Conclusions:

• Preoperative administration of levosimendan is effective in improving hemodynamic status in high-risk cardiosurgical patients.
• Levosimendan treatment is associated with reduced need for cardiotonic support, shorter ICU stays, and improved survival rates.
• Levosimendan represents a valuable therapeutic option for optimizing patients prior to major cardiac surgery.